Predicting the therapeutic response to cognitive behavioural therapy in patients with pharmacoresistant obsessive-compulsive disorder

Neuroendocrinology Letters

Volumn 30, Issue 5, 2009, Pages 615-623

  Praško, Ján ^a,b,c,d   Raszka, Michal ^c,d   Adamcova, Katarina ^c   Grambal, Ales ^a,b   Koprivova, Jana ^c,d   Kudrnovska, Hana ^c   Latalova, Klara ^a,b   Vyskocilova, Jana ^c  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CBT; Dissociation; Insight; Obsessive compulsive disorder; Prediction of therapeutic response; Resistance; SSRI

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT;

ADULT; AGGRESSION; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DISEASE DURATION; DISSOCIATIVE DISORDER; DISSOCIATIVE EXPERIENCE SCALE; FEMALE; HUMAN; INTROSPECTION; MALE; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; REMISSION; SEX DIFFERENCE; SOMATOFORM DISSOCIATION QUESTIONNAIRE; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 77649250019     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abrahamowitz JS (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 65: 44-52.
2. Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J (2001). Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry. 62: 535-540.
3. Beck AT & Emery G: Anxiety disorders and phobias: A cognitive perspective. New York, Basic Books: (1985).
4. Bernstein EM, Putnam FW (1986). Development, Reliability, and Validity of a Dissociation Scale. J. Nerv. Ment. Dis. 174(12): 727-735.
5. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 11(7): 622-632.
6. Davidson JTR a Connor KM (2004).Treatment of anxiety disorders. In: Schatzberg AF a Nemeroff CB (eds): Textbook of psychopharmacology. American Psychiatric Press, Washington; 913-934.
7. Denys D, Fineberg N, Carey PD, Stein DJ (2007). Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry. 61(3): 412-4.
8. Denys D, van Nieuwerburgh F, Deforce D, Westenberg HGM (2007). Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 68: 747-753.
9. Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD, Emslie G, Carpenter D (2003). Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol. 13 Suppl 1: S19-S29.
10. Goodman WK, Rasmussen SA, Price LH et al: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). New Haven, CT, YaIe University Department of Psychiatry, (1986).
11. Goff DC, Olin JA, Jenike MA, Baer L, Buttolph ML (1992). Dissociative symptoms in patients with obsessive-compulsive disorder. J Nerv Ment Dis. 180: 332-337.
12. Greist JH a Jefferson JW (1998). Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry. 173 (suppl 35): 64-70.
13. Greist JH, Bandelow B, Hollander E et al. (2003). Long-term treatment of obsessive-compulsive disorder in adults. CNS Spectrums. 8: 7-16.
14. Guy W (ed.): ECDEU Assessment manual for psychopharmacology. Rockville, U.S. DHEW (1976).
15. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol. 32: 50-55.
16. Hantouche EG, Bouhassira M, Lancrenon S (2000). Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study. Encephale. 26: 73-83.
17. Kaplan A, Hollander E (2003). A review of pharmacologic treatments for obsessive - compulsive disorder. Psychiatric Services. 54(8):1111-1118.
18. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M (2005). Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 66(3): 353-359.
19. Lecrubier Y, Sheehan DV, and Weiller E, et al. (1997). The MINI-international neuropsychiatrie interview (M.I.N.I.): a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 12: 224-231.
20. Leonard HL, Swedo SE, Lenane MC, Rettew DC, Hamburger SD, Bartko JJ, Rapoport JL (1993). A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry. 50: 429-439.
21. March JS, Frances A, Kahn DA, Carpenter D (1997). The expert consensus guidelines series. Treatment of obsessive-compulsive disorder. J Clin Psychiatry. 58: (Suppl): 1-72.
22. Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L (1999). Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 156: 1409-1416.
23. McDougle CJ, Fleischmann RL, Epperson CN, Wayslink S, Leckmann JF, Price LH (1995). Risperidone addition in fluvoxamine refractory obsessive compulsive disorder: three cases. J Clin Psychiat. 56: 526-528.
24. th revision. Mental and behavioural disorders: Research diagnostic criteria, Prague, Prague Psychiatric Centre (1996), 179pp.
25. Nakao T, Nakatani E, Nabeyama M, Yoshioka K, Tomita M, Nakagawa A (2005). Duration effect on neuropsychological function and treatment response of OCD. Seishin Shinkeigaku Zasshi. 107: 1286-1298.
26. NICE (2006). Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body-dysmorphic disorder. National Collaborating Centre for Mental Health, Publ British Psychological Society and the Royal College of Psychiatrists, UK 2006. Also www.nice.org.uk.
27. Nijenhuis ERS, Spinhoven P, Van Dyck R, Van Der Hart O, Vanderlinden J (1996). Somatoform Dissociation Questionaire. J. Nerv. Ment. Dis. 184(11): 688-694.
28. Perse T (1988). Obsessive-compulsive disorder: A treatment review. J Clin Psychiatry. 49: 48-55.
29. Pigott TA, Seay S (1997). Pharmacotherapy of obsessive-compulsive disorder. Int Rev Psychiatry. 9: 133-147.
30. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1995). Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry. 56: 368-373.
31. Rufer M, Held D, Cremer J, Fricke S, Moritz S, Peter H, Hand I (2006). Dissociation as a predictor of cognitive behavior therapy outcome in patients with obsessive-compulsive disorder. Psychother Psychosom. 75: 40-46.
32. Saxena S, Maidment KM, VapnikT, Golden G, Rishwain T, Rosen RM, Tarlow G, Bystritsky A (2002). Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. J Clin Psychiatry. 63: 21-27.
33. Saxena S, Brody AL, Maidment KM, Baxter LR Jr (2007): Paroxetine treatment of compulsive hoarding. J Psychiatr Res. 41: 481-487.
34. Shetti CN, Reddy YC, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, Siddequehusen MU, Raghunandanan S (2005). Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry. 66: 1517-1523.
35. Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, Davies SO, Campeas R (2004). Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety. 19: 225-233.
36. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 23(1): CD001765.
37. Stewart SE, Stack DE, Wilhelm S (2008). Severe obsessive-compulsive disorder with and without body dysmorphic disorder: clinical correlates and implications. Ann Clin Psychiatry. 20: 33-38.
38. Watson D, Wu KD, Cutshall C (2004). Symptom subtypes of obsessive-compulsive disorder and their relation to dissociation. J Anxiety Disord. 18: 435-58.
39. Weissman MM, Bland RC, Canino GJ, et al. (1994). The cross national epidemiology of obsessive - compulsive disorder. J Clin Psychiatry. 55 (Suppl 3): 5-10.
40. Zohar J, Hollander E, Stein DJ et al. (2007). Cape Town consensus of the treatment of obsessive compulsive disorder. CNS Spectrums. 2 (suppl 3): 59-63.